Ivan Špıčka

15.6k citations

141 papers · 3.7k indexed · 2 hit papers · h-index 24

Impact in

Hematology top 0.2%
- Multiple Myeloma Research and Treatments
Oncology top 1%
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology

Papers in ⓘ

Hematology 131
- Multiple Myeloma Research and Treatments 129
Oncology 83
- Peptidase Inhibition and Analysis 48
- Cancer Treatment and Pharmacology 33

Co-authors: Pieter Sonneveld (13 shared papers)Antonio Palumbo (12 shared papers)Andrew Spencer (10 shared papers)María‐Victoria Mateos (25 shared papers)Tamás Masszi (17 shared papers)Roman Hájek (58 shared papers)Meral Beksaç (11 shared papers)William Deraedt (6 shared papers)
Journals: Journal of Clinical Oncology (27 papers)Blood (26 papers)British Journal of Haematology (8 papers)European Journal Of Haematology (7 papers)Haematologica (5 papers)
Partner nations: Czechia United States Spain

In The Last Decade

Ivan Špıčka

126 papers receiving 3.6k citations

Hit Papers

align trajectories log scale

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma 2016 · 1.1k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2016 New England Journal of Medicine
2007 Journal of Clinical Oncology

Peers

Countries citing papers authored by Ivan Špıčka

Since Specialization

Citations

This map shows the geographic impact of Ivan Špıčka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ivan Špıčka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ivan Špıčka more than expected).

Fields of papers citing papers by Ivan Špıčka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ivan Špıčka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ivan Špıčka. The network helps show where Ivan Špıčka may publish in the future.

Co-authors

The 25 scholars most cited alongside Ivan Špıčka, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ivan Špıčka Line = papers co-authored together Ivan Špıčka links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 141 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma New England Journal of Medicine ·Antonio Palumbo, Asher Chanan‐Khan, Katja Weisel, Ajay K. Nooka, Tamás Masszi, Meral Beksaç, Ivan Špıčka, Vânia Hungria, (unknown), María‐Victoria Mateos, Tomer M. Mark, Ming Qi, Jordan M. Schecter, Himal Amin, Xiang Qin, William Deraedt, Tahamtan Ahmadi, Andrew Spencer, Pieter Sonneveld Hit paper breakdown →	2016	1056
2	Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression Journal of Clinical Oncology ·Robert Z. Orlowski, Arnon Nagler, Pieter Sonneveld, Joan Bladé, Roman Hájek, Andrew Spencer, Jesús F. San Miguel, Tadeusz Robak, Anna Dmoszyńska, Noemi Horvath, Ivan Špıčka, Heather J. Sutherland, А. Н. Суворов, Sen Hong Zhuang, Trilok Parekh, Liang Xiu, Zhilong Yuan, Wayne Rackoff, Jean‐Luc Harousseau Hit paper breakdown →	2007	505
3	Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial Journal of Clinical Oncology ·María‐Victoria Mateos, Paul G. Richardson, Rudolf Schlag, Nuriet K. Khuageva, Meletios Α. Dimopoulos, Ofer Shpilberg, Martin Kropff, Ivan Špıčka, Maria Teresa Petrucci, Antonio Palumbo, Olga Samoilova, Anna Dmoszyńska, Abdulkadyrov Km, Rik Schots, Bin Jiang, Dixie Esseltine, Kevin Liu, Andrew Cakana, Helgi van de Velde, Jesús F. San Miguel	2010	312
4	Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma Blood ·Heinz Ludwig, Roman Hájek, Elena Tóthová, Johannes Drach, Zdeněk Adam, Boris Labar, Miklós Egyed, Ivan Špıčka, Heinz Gisslinger, Richard Greil, Ingrid Kühn, Niklas Zojer, Axel Hinke	2008	148
5	A phase 2, randomized, double‐blind, placebo‐controlled study of siltuximab (anti‐IL‐6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma American Journal of Hematology ·Robert Z. Orlowski, Liana Gercheva, Cathy Williams, Heather J. Sutherland, Tadeusz Robak, Tamás Masszi, Vesselina Goranova‐Marinova, Meletios Α. Dimopoulos, James D. Cavenagh, Ivan Špıčka, Ângelo Maiolino, А. Н. Суворов, Joan Bladé, Olga Samoylova, Thomas A. Puchalski, Manjula Reddy, Rajesh Bandekar, Helgi van de Velde, Hong Xie, Jean‐Franςois Rossi	2014	115
6	Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study European Journal Of Haematology ·Meletios Α. Dimopoulos, María-Victoria Mateos, Paul G. Richardson, Rudolf Schlag, Nuriet K. Khuageva, Ofer Shpilberg, Martin Kropff, Ivan Špıčka, Antonio Palumbo, Ka Lung Wu, Dixie‐Lee Esseltine, Kevin Liu, William Deraedt, Andrew Cakana, Helgi van de Velde, Jesús F. San Miguel	2010	100
7	Once‐weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production British Journal of Haematology ·Mario Cazzola, Yves Béguin, Janusz Kłoczko, Ivan Špıčka, Bertrand Coiffier	2003	99
8	Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial Journal of Clinical Oncology ·Pieter Sonneveld, Asher Chanan‐Khan, Katja Weisel, Ajay K. Nooka, Tamás Masszi, Meral Beksaç, Ivan Špıčka, Vânia Hungria, Markus Munder, María‐Victoria Mateos, Tomer M. Mark, Mark‐David Levin, Tahamtan Ahmadi, Xiang Qin, Wendy Garvin Mayo, Xue Gai, Jodi Carey, Robin Carson, Andrew Spencer	2022	63
9	Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma Journal of Clinical Oncology ·A. Keith Stewart, Meletios Α. Dimopoulos, Tamás Masszi, Ivan Špıčka, Albert Oriol, Roman Hájek, Laura Rosiñol, David S. Siegel, Rubén Niesvizky, Andrzej Jakubowiak, Jesús F. San Miguel, Heinz Ludwig, Jacqui Buchanan, Kim Cocks, Xinqun Yang, Biao Xing, Naseem J. Zojwalla, Margaret Tonda, Philippe Moreau, Antonio Palumbo	2016	59
10	Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma Journal of Clinical Oncology ·Heinz Ludwig, Luísa Viterbo, Richard Greil, Tamás Masszi, Ivan Špıčka, Ofer Shpilberg, Roman Hájek, Anna Dmoszyńska, Bruno Paiva, María‐Belén Vídriales, Graça Esteves, Anne Marie Stoppa, Don Robinson, Deborah Ricci, Andrew Cakana, Christopher Enny, Huaibao Feng, Helgi van de Velde, Jean‐Luc Harousseau	2012	58
11	Gain of 1q21 Is an Unfavorable Genetic Prognostic Factor for Multiple Myeloma Patients Treated with High-Dose Chemotherapy Biology of Blood and Marrow Transplantation ·Pavel Němec, Zuzana Zemanová, Henrieta Grešlíková, K Michalová, Hana Filková, Jana Tajtlová, Dana Kralova, Renata Kupská, Jan Smetana, Marta Krejčí, Luděk Pour, Lenka Zahradová, Viera Sandecká, Zdeněk Adam, Tomáš Büchler, Ivan Špıčka, Evžen Gregora, Petr Kuglík, Roman Hájek	2009	54
12	Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial Journal of Clinical Oncology ·Meletios Α. Dimopoulos, Ivan Špıčka, Hang Quach, Albert Oriol, Roman Hájek, Mamta Garg, Meral Beksaç, Sara Bringhen, Eirini Katodritou, Wee Joo Chng, Xavier Leleu, Shinsuke Iida, María‐Victoria Mateos, Gareth J. Morgan, Alexander Vorog, Richard Labotka, Bingxia Wang, Antonio Palumbo, Sagar Lonial, (unknown)	2020	53
13	Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study British Journal of Haematology ·Meletios Α. Dimopoulos, A. Keith Stewart, Tamás Masszi, Ivan Špıčka, Albert Oriol, Roman Hájek, Laura Rosiñol, David S. Siegel, Georgi Mihaylov, Vesselina Goranova‐Marinova, Péter Rajnics, Aleksandr Suvorov, Rubén Niesvizky, Andrzej Jakubowiak, Jesús F. San Miguel, Heinz Ludwig, Antonio Palumbo, Mihaela Obreja, Sanjay Aggarwal, Philippe Moreau	2017	45
14	Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment Blood Cancer Journal ·Meletios Α. Dimopoulos, A. Keith Stewart, Tamás Masszi, Ivan Špıčka, Albert Oriol, Roman Hájek, Laura Rosiñol, David S. Siegel, Georgi Mihaylov, Veselina Goranova‐Marinova, Péter Rajnics, Aleksandr Suvorov, Rubén Niesvizky, Andrzej Jakubowiak, Jesús F. San Miguel, Heinz Ludwig, Sunhee Ro, Sanjay Aggarwal, Philippe Moreau, Antonio Palumbo	2017	44
15	Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma Leukemia Research ·Paul G. Richardson, Constantine S. Mitsiades, Jacob P. Laubach, Roman Hájek, Ivan Špıčka, Meletios Α. Dimopoulos, Philippe Moreau, David S. Siegel, Sundar Jagannath, Kenneth C. Anderson	2013	42
16	Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes Annals of Hematology ·Xavier Leleu, Thomas G. Martin, Katja Weisel, Fredrik Schjesvold, Shinsuke Iida, Fabio Malavasi, Salomon Manier, Chang‐Ki Min, Enrique M. Ocio, Charlotte Pawlyn, Aurore Perrot, Hang Quach, Joshua Richter, Ivan Špıčka, Kwee Yong, Paul G. Richardson	2022	40
17	Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial Leukemia & lymphoma ·Pavel Němec, Zuzana Zemanová, Petr Kuglík, K Michalová, Jana Tajtlová, Petra Kaisarová, Alexandra Oltová, Hana Filková, Milena Holzerová, Jana Balcárková, Marie Jarošová, Jana Rabasová, Martina Hrubá, Ivan Špıčka, Evžen Gregora, Zdeněk Adam, Vlastimil Ščudla, Vladimír Maisnar, M Schützová, Roman Hájek, (unknown)	2011	34
18	Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma Cancer ·Robert Z. Orlowski, Arnon Nagler, Pieter Sonneveld, Joan Bladé, Roman Hájek, Andrew Spencer, Tadeusz Robak, Anna Dmoszyńska, Noemi Horvath, Ivan Špıčka, Heather J. Sutherland, А. Н. Суворов, Liang Xiu, Andrew Cakana, Trilok Parekh, Jesús F. San Miguel	2016	32
19	Combined treatment of primary vitreoretinal lymphomas significantly prolongs the time to first relapse British Journal of Ophthalmology ·Aneta Klímová, Jarmila Heissigerová, (unknown), Michaela Brichová, Robert Pytlík, Ivan Špıčka, Kateřina Mrázová, Jana Karolová, Petra Svozílková	2018	31
20	Nelfinavir Inhibits the TCF11/Nrf1-Mediated Proteasome Recovery Pathway in Multiple Myeloma Cancers ·Dominika Fassmannová, František Sedlák, Jindr̂ich Sedláĉek, Ivan Špıčka, Klára Grantz Šašková	2020	29

About Ivan Špıčka

Ivan Špıčka is a scholar working on Hematology, Oncology, Genetics, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 141 papers that have together received 3.7k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (129 papers), Protein Degradation and Inhibitors (51 papers), Peptidase Inhibition and Analysis (48 papers), Cancer Treatment and Pharmacology (33 papers), Chronic Lymphocytic Leukemia Research (21 papers), Cancer therapeutics and mechanisms (13 papers), Monoclonal and Polyclonal Antibodies Research (12 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers). The work is most often cited by research in Hematology (3.1k citations), Oncology (2.1k citations), Genetics (474 citations), Molecular Biology (2.4k citations) and Immunology (249 citations). Ivan Špıčka has collaborated with scholars based in Czechia, United States and Spain. Frequent co-authors include Pieter Sonneveld, Antonio Palumbo, Andrew Spencer, María‐Victoria Mateos, Tamás Masszi, Roman Hájek, Meral Beksaç, William Deraedt, Katja Weisel and Jesús F. San Miguel. Their work appears in journals such as Journal of Clinical Oncology, Blood, British Journal of Haematology, European Journal Of Haematology and Haematologica.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact